GERN · Nasdaq · CIK 0000886744

GERON CORP

GERON CORP’s most recent SEC filing in our snapshot is a Form 4 filed on Oct 1, 2026. Its EDGAR record lists 14 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
—
Net income, FY2025
-$83.5M
Form 4 filings on record, past 12 months
14

Company overview

Legal name (as filed)
GERON CORP
Ticker
GERN
SEC Central Index Key (CIK)
0000886744
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
FOSTER CITY, CA
State or country of incorporation
DE
Fiscal year ends
December 31
SEC filer category
Large accelerated filer
Position in SEC ticker list
#2627 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from GERON CORP’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
$1.4MFY2021$596.0KFY2022$237.0KFY2023n/aFY2024n/aFY2025
Net income
-$116.1MFY2021-$141.9MFY2022-$184.1MFY2023-$174.6MFY2024-$83.5MFY2025
GERN annual results
ItemFY2021
ended Dec 31, 2021
FY2022
ended Dec 31, 2022
FY2023
ended Dec 31, 2023
FY2024
ended Dec 31, 2024
FY2025
ended Dec 31, 2025
Revenue$1.4M$596.0K$237.0K——
Net income-$116.1M-$141.9M-$184.1M-$174.6M-$83.5M
Diluted EPS-$0.35-$0.37-$0.32-$0.27-$0.13
Total assets$226.0M$190.6M$394.1M$593.8M$570.5M
Cash and equivalents$34.9M$56.8M$70.0M$79.0M$77.6M

XBRL tags used: revenue = RevenueFromContractWithCustomerExcludingAssessedTax; netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

GERN latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Mar 2, 202610-KAnnual report· period Dec 31, 2025Document · Index
Aug 5, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Aug 6, 20268-KResults of operations· period Aug 5, 2026Document · Index
Apr 7, 2026DEF 14ADefinitive proxy statement· period May 20, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about GERON CORP, by form type:

4 ×148-K ×7SCHEDULE 13G/A ×53 ×3SCHEDULE 13G ×210-Q ×2144 ×1S-8 ×1ARS ×1DEFA14A ×1DEF 14A ×1S-3ASR ×110-K ×1
GERN recent filings
FiledFormWhat it isOriginal
Oct 1, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 30, 2026Document · Index
Aug 14, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Aug 7, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Aug 6, 20268-KResults of operations· period Aug 5, 2026Document · Index
Aug 5, 2026S-8Registration of employee benefit plan securitiesDocument · Index
Aug 5, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Jul 1, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 30, 2026Document · Index
May 27, 20268-KDirector or officer change; Shareholder vote results· period May 20, 2026Document · Index
May 26, 20264Statement of changes in beneficial ownership (insider trade)· period May 20, 2026Document · Index
May 26, 20264Statement of changes in beneficial ownership (insider trade)· period May 20, 2026Document · Index
May 26, 20264Statement of changes in beneficial ownership (insider trade)· period May 20, 2026Document · Index
May 26, 20264Statement of changes in beneficial ownership (insider trade)· period May 20, 2026Document · Index
May 26, 20264Statement of changes in beneficial ownership (insider trade)· period May 20, 2026Document · Index
May 15, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
May 8, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
May 6, 202610-QQuarterly report· period Mar 31, 2026Document · Index
Apr 14, 20264Statement of changes in beneficial ownership (insider trade)· period Apr 13, 2026Document · Index
Apr 14, 20263Initial statement of beneficial ownership· period Apr 13, 2026Document · Index
Apr 7, 2026ARSARS· period Dec 31, 2025Document · Index
Apr 7, 2026DEFA14AAdditional proxy soliciting materialsDocument · Index
Apr 7, 2026DEF 14ADefinitive proxy statement· period May 20, 2026Document · Index
Apr 1, 20264Statement of changes in beneficial ownership (insider trade)· period Mar 31, 2026Document · Index
Mar 26, 20264Statement of changes in beneficial ownership (insider trade)· period Mar 25, 2026Document · Index
Mar 26, 20263Initial statement of beneficial ownership· period Mar 25, 2026Document · Index
Mar 26, 20264Statement of changes in beneficial ownership (insider trade)· period Mar 25, 2026Document · Index
Mar 26, 20263Initial statement of beneficial ownership· period Mar 25, 2026Document · Index
Mar 26, 20268-KDirector or officer change· period Mar 25, 2026Document · Index
Mar 26, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Mar 3, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Mar 2, 2026S-3ASRSimplified registration statementDocument · Index
Mar 2, 202610-KAnnual report· period Dec 31, 2025Document · Index
Feb 25, 20268-KResults of operations· period Feb 25, 2026Document · Index
Feb 19, 20264Statement of changes in beneficial ownership (insider trade)· period Feb 17, 2026Document · Index
Feb 19, 20264Statement of changes in beneficial ownership (insider trade)· period Feb 17, 2026Document · Index
Feb 13, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Jan 12, 20268-KRegulation FD disclosure· period Jan 12, 2026Document · Index
Jan 6, 20268-KMaterial agreement· period Jan 5, 2026Document · Index
Jan 5, 20264Statement of changes in beneficial ownership (insider trade)· period Dec 31, 2025Document · Index
Dec 16, 20258-KExit or disposal costs· period Dec 10, 2025Document · Index
Dec 15, 2025144Notice of proposed sale of securitiesDocument · Index

Insider filing activity

14 Form 4 filings appear in GERON CORP’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations· Companies headquartered in California

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0000886744 and XBRL company facts. GERON CORP on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.